CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 9 ...

SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the Goldman Sachs 46th Annual Global Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Tuesday, June 10, 2025, at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on ...

RIMOUSKI, Quebec, May 27, 2025 (GLOBE NEWSWIRE) -- Puma Exploration Inc. (TSXV: PUMA) (“Puma”), announces that its subsidiary, Murray Brook Minerals Inc. (“MBM” or “Murray Brooks Minerals”) has closed a non-brokered offering consisting of 4,400,000 flow-through common shares (the "FT Shares") of MBM at a price of C$0.05 per FT Share for aggregate gross proceeds of $220,000 (the “FT Offering”). Following the FT Offering, Murray Brook Minerals has now 28,044,165 common shares issued and outstanding, with no w ...

SINGAPORE, May 27, 2025 (GLOBE NEWSWIRE) -- Multi Ways Holdings Limited (“Multi Ways”, the “Company” or the “Issuer”) (NYSE American: MWG), a leading supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region, today announced fiscal year 2024 financial results. "We are pleased to report on the strategic advancements Multi Ways Holdings Limited has achieved over the past year," said Mr. James Lim, Chairman and Chief Executive Officer of Multi Ways Ho ...

Core Viewpoint - MicroAlgo Inc. is focused on enhancing the accuracy and reliability of quantum algorithms by optimizing quantum error correction algorithms, which are essential for detecting and correcting errors in qubits during quantum computation [1][2]. Group 1: Quantum Error Correction Algorithms - The company introduces redundant qubits and specific measurement operations to detect and correct errors in qubits, ensuring the accuracy of quantum computation [2][7]. - The first step in quantum error correction involves encoding quantum information using redundant qubits to form a quantum codeword, which helps retain data despite noise [3]. - Error detection is performed through specific measurement operations on auxiliary qubits, allowing for the identification of errors in the quantum codeword [4]. Group 2: Error Correction Process - Once errors are detected, a series of complex quantum operations are executed to restore erroneous qubits to their correct states, emphasizing the need for efficient error correction algorithms [5]. - The algorithm undergoes iterative optimization, continuously repeating encoding, detection, and correction processes to reduce error rates and improve algorithm accuracy [6]. Group 3: Applications and Prospects - MicroAlgo's quantum error correction algorithm has broad application prospects in quantum communication, enhancing security and anti-interference capabilities, particularly for quantum key distribution [8]. - In quantum computing, the algorithm reduces qubit error rates, improving the reliability of quantum algorithms and supporting their practical applications [8]. - The algorithm can also be applied in quantum simulation and optimization, providing new tools for research and development in these areas [8]. Group 4: Company Overview - MicroAlgo Inc. is dedicated to developing bespoke central processing algorithms, offering solutions that integrate these algorithms with software or hardware to enhance customer satisfaction and achieve technical goals [9][10].

RESTON, Va, May 27, 2025 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge” or the “Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced how President Trump's recent nuclear energy Executive Orders (the “Executive Orders”) create opportunities for the company's advanced fuel technology and business strategy. On May 23, 2025, President Trump signed four Executive Orders representing the most significant policy shift toward nuclear energy in decades. These executive o ...

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock ConferenceDate: June 3, 2025Location: Chicago, ILFormat: Mana ...

SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (the “NMPA”) has approved two supplemental new drug applications for the ongericimab injection (a recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA (君适达® ...

Core Insights - Immutep Limited's investigator-initiated EFTISARC-NEO Phase II trial has successfully met its primary endpoint, demonstrating a significant increase in tumour hyalinization/fibrosis in patients with resectable soft tissue sarcoma (STS) when treated with eftilagimod alfa (efti) combined with radiotherapy and KEYTRUDA® [1][7]. Company Overview - Immutep is a late-stage biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune diseases, particularly leveraging the Lymphocyte Activation Gene-3 (LAG-3) pathway [7]. - The company is pioneering the understanding and advancement of therapeutics related to LAG-3, aiming to provide novel treatment options for patients and maximize shareholder value [7]. Trial Details - The EFTISARC-NEO trial showed a median of 50% tumour hyalinization/fibrosis in a preliminary analysis of 21 patients, significantly exceeding the prespecified median of 35% [3]. - The trial is primarily funded by a grant from the Polish government, with a total enrollment of 40 patients completed in January 2025 [3][4]. Medical Significance - Tumour hyalinization/fibrosis serves as an early surrogate endpoint linked to improved overall survival and recurrence-free survival in STS patients [2]. - STS is classified as an orphan disease with a high unmet medical need and poor prognosis, with an estimated 13,520 new cases and 5,420 deaths in the U.S. in 2025 [4]. Eftilagimod Alfa (efti) Profile - Efti is a proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity, enhancing the immune response against cancer [5]. - Efti is under evaluation for various solid tumours, including non-small cell lung cancer and head and neck squamous cell carcinoma, and has received Fast Track designation from the FDA for certain indications [6].

Expands access to precision-based care through at-home DNA testing and personalized health plansVANCOUVER, British Columbia and LAS VEGAS, May 27, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform delivering compliant mobile and telehealth services across all 50 U.S. states, is pleased to announce the launch of a new direct-to-consumer genetic testing and personalized wellness solution via its VS ...